We could not find any results for:
Make sure your spelling is correct or try broadening your search.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to... FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. Show more
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of...
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the...
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on...
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (โFibroBiologicsโ), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (โFibroBiologicsโ) and Charles River Laboratories (โCharles Riverโ), a leading global drug discovery, development...
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (โFibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.05 | 2.27272727273 | 2.2 | 2.2821 | 1.93 | 123305 | 2.12345274 | CS |
4 | -0.16 | -6.63900414938 | 2.41 | 2.98 | 1.93 | 118950 | 2.41732744 | CS |
12 | -0.97 | -30.1242236025 | 3.22 | 3.89 | 1.93 | 158013 | 2.83713814 | CS |
26 | -4 | -64 | 6.25 | 6.7 | 1.0779 | 303268 | 3.19346412 | CS |
52 | -27.75 | -92.5 | 30 | 55 | 1.0779 | 227772 | 5.08742001 | CS |
156 | -27.75 | -92.5 | 30 | 55 | 1.0779 | 227772 | 5.08742001 | CS |
260 | -27.75 | -92.5 | 30 | 55 | 1.0779 | 227772 | 5.08742001 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions